PRESS RELEASEAB SCIENCE PROVIDES INITIAL PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIAParis, 16 October 2025, 9pm CETAB Science SA (Euronext - FR0010557264 - AB) today provides an update on its AB8939 program in acute myeloid leukemia (AML). Second, AB8939 targets leukemia cancer stem cells though inhibition of ALDH and favors the bone marrow repopulation of normal progenitors. This combination is expected to be less toxic than azacitidine + venetoclax as first-line treatment for AMLBoth molecules have different and complementary targets in cancer cells. Venetoclax mechanism of action is to inhibit BCL2 pathway, a protein that prevents apoptosis (programmed cell death) in cancer cells. Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.